Blog
NPs Have Top Job in US; PAs Rank Fifth: US News and World Report
Nurse Practitioner is the best job in the US, according to the 2024 Best Jobs Report from US News and World Report. In the Health Care field specifically, NP holds the top job spot, followed by Physician Assistant in second place. PA is the fifth top job in the US...
Psoriasis Linked to Poor Sleep Quality
By Joe Gorelick, MSN, FNP-C Psoriatic disease is associated with poor sleep quality and high rates of sleep disturbance, according to the most recent meta-analysis of case-control or cohort studies that assessed sleep quality in individuals with psoriatic disease....
Zelsuvmi from Ligand Gets FDA Nod for Molluscum
Zelsuvmi™ (berdazimer topical gel, 10.3%) from Ligand Pharmaceuticals, Inc. is now FDA approved for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older. It is the first novel drug approved for the treatment of...
FDA Approves Novel Therapy for Management of Patients with EB
Filsuvez® (birch triterpenes) topical gel from Chiesi Global Rare Diseases has received FDA approval for the treatment of partial thickness wounds in patients 6 months and older with Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB)....
Zoryve Gets FDA Nod for Seborrheic Dermatitis in Patients as Young as Nine
Zoryve (roflumilast) topical foam, 0.3% from Arcutis Biotherapeutics has received FDA approval for the treatment of seborrheic dermatitis in individuals 9 years of age and older. Once-daily, steroid-free Zoryve is the first drug approved for seborrheic dermatitis with...
FDA Approves Expanded Indication for Tralokinumab for Pediatric AD
FDA has approved the expanded label for LEO Pharma’s Adbry® (tralokinumab-ldrm) to include pediatric patients aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those...
Comprehensive Meta-analysis Sheds Light on Safety of JAKs for Management of AD
By Joe Gorelick, MSN, FNP-C With 10 JAK inhibitors now approved by the FDA for use in the US across a range of indications, the significance of the boxed warning for JAK inhibitors to include the risk of major adverse events remains unclear. The lack of clarity with...
3 Novel Drugs Approved in Dermatology in 2023: FDA NDA Approvals Up vs. 2022
-- UPDATE: NDA Approvals for 2023 now stand at 54, with a fourth dermatologic indication approved! Filsuvez® (birch triterpenes) topical gel from Chiesi Global Rare Diseases has received FDA approval for the treatment of partial thickness wounds in patients 6 months...
Investigational Compounds Progress for Acne, AD
The Phase III clinical trial is now underway to evaluate fatty acid synthase (FASN) inhibitor ASC40 (Denifanstat) from Ascletis Pharma, Inc. for treatment of moderate to severe acne vulgaris. The randomized, double-blind, placebo-controlled, multicenter clinical trial...
FDA Accepts Supplemental NDA for Roflumilast 0.15% Cream for AD in Adults, Children as Young as Six
The FDA has accepted the supplemental new drug application (sNDA) from Arcutis Biotherapeutics, Inc. for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. The FDA assigned the application a Prescription Drug User...